1 / 21

HIV/HBV coinfection in HIV-infected children

HIV/HBV coinfection in HIV-infected children. Pope Kosalaraksa, M.D. Department of Pediatrics Faculty of Medicine Khon Kaen University. Outline. Epidemiology – prevalence Coinfection and risk of transmission Natural history of HBV infection perinatally/adults HBV/HIV coinfection: clinical

christian-workman
Télécharger la présentation

HIV/HBV coinfection in HIV-infected children

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV/HBV coinfectionin HIV-infected children Pope Kosalaraksa, M.D. Department of Pediatrics Faculty of Medicine Khon Kaen University

  2. Outline • Epidemiology – prevalence • Coinfection and risk of transmission • Natural history of HBV infection perinatally/adults • HBV/HIV coinfection: clinical • HBV vaccine: seroprotection, booster • Treatment

  3. Hepatitis B infection • Asymptomatic >>> Symptomatic • Recover (immune) >> carrier >> >> cirrhosis >> cancer • HIV-infected children more rapid/severe than adult/non HIV children?

  4. HBV/HIV co-infection In adults: • higher level of HBV viremia • increase hepatotoxicity • increase liver-related morbidity and mortality In children: • little information • unique population (immune tolerant) • liver-related morbidity, mortality

  5. Epidemiology • 350 million: chronic HBV infection • 0.5–1.2 millions: die each year • Pregnant women (Africa) - prevalence : HBV monoinfection 4.0 - 17.1% : HBV/HIV coinfection 0.4 - 7.1%

  6. HIV/HBV co-infection in children Healy SA, et al. Expert Rev Anti Infect Ther 2013;11:251-63.

  7. HBV and HIV • Common transmission routes : perinatal : horizontal : parenteral : sexual • Higher prevalence of HBV infection in HIV than non-HIV population

  8. Risk of developing chronic HBV • Age at time of infection : Neonate (mother HBeAg+) up to 90% : After neonate – 5 years 20-30% : Immunocompetent adults < 5-10% • Maternal HBeAg/anti-HBe status : < 10% - HBeAg -ve/anti-HBe +ve

  9. HBV vaccine in HIV children • may have less protection : less robust initial immune response : waning of anti-HBs • After cART : poor restore anti-HBs : 1-40% had protective Ab >10 IU/ml

  10. Immune response to HBV vaccine in HIV children • International Maternal Pediatric Adolescent AIDS Clinical Trial group : 204 HIV children with cART : mean age - 9 years : history of 3 doses of a primary HBV vaccination : 24% had protective anti-HBs antibody : 45%- seropositive at 8 weeks after a booster Abzug MJ, et al. J Infect Dis 2009:200:935-46.

  11. Booster response in HIV children • 64 HIV-infected children : median age - 10 years : median cART - 31 months : complete HBV vaccination : no seroprotective Ab – 87% • Seroprotective Ab after booster : 17.0% after 1st dose : 82.5% after 2nd dose : 92.0% after 3rd dose Lao-Araya M, et al. Vaccine 2011;29:3977-81.

  12. Extrapolating from adults’ studies • HBV/HIV co-infected children : more active liver disease : more rapid progression to hepatic fibrosis and cirrhosis

  13. HBV infection perinatally

  14. Phases of chronic HBV infection

  15. Treatment of HBV in children • Not cytopathic • Immune response: hepatic damage • Immune tolerant phase - not recommended : high HBV DNA, normal ALT • Immune active phase - recommended : elevated ALT, mod-sever liver inflam. : non-invasive measures – transient elastography

  16. Treatment of HBV in HIV children • Concern: high risk progression to hepatic fibrosis • Hepatic foundation expert: treat all regardless phase of infection • Other group: same as non HIV children • No published guideline: indication for Rx. • Antiviral drugs (HBV) : IFN-α, nucleos(t)ide anlogue

  17. Antiviral drugs • IFN-α – preferred treatment, 26% efficacy - poor tolerant: flu-like symptom • Lamivudine (3TC), FTC - good safety profile - risk of resistance (monotherapy) • Adefovir - increase in serum creatinine • Entecavir, Tenofovir - high genetic barrier - high efficacy(78-86%)

  18. HBV monotherapy in HIV • Lamivudine (3TC) resistance1 : 50% within 2 years : >90% at 4 years • In children2 : 69% HBV DNA > 105copies/ml : rtM204V/I mutation – 75% 1. Healy SA, et al. Expert Rev Anti Infect Ther 2013;11:251-63. 2. Aurpibul L, et al. Pediatr Infect Dis J 2012;31:943-7.

  19. Antiviral agents for HBV

  20. Treatment strategy: HIV/HBV • Not require HBV treatment : use lamivudine sparing ART • Require HBV treatment : use tenofovir/lamivudine • Hepatic flare after starting ART : 25% in adults : in children – immunetolerant (unknown)

  21. HIV/HBV: summary • Similar transmission route, drugs • Effect of HBV disease progression • HBV vaccine response rate : low, need reimmunization • Choice of ARV – depend on HBV status • Long survival in HIV children : long-term effect of HBV?? • Screening and Prevention****

More Related